Autres langues MindBio Therapeutics Corp.

Actions

MBIO

CA60256C1086

Marché Fermé - Canadian Securities Exchange Autres places de cotation 15:30:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,04 ^CAD	0,00 %		+14,29 %	+60,00 %

20/06	MindBio Therapeutics Corp. MindBio Therapeutics Corp. présente les données de durabilité des essais cliniques de phase 2A menés auprès de patients dépressifs testant le MB22001	CI
12/06	Mindbio Therapeutics présente des données secondaires : Amélioration des résultats psychologiques et de l'innocuité chez les patients dépressifs de l'essai de phase 2A sur la dépression	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001	20/06
MindBio Therapeutics Reports Secondary Data, Improvement of Psychological Outcomes and Safety Results in Depressed Patients from Phase 2A Depression Trial	13/06
Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial	12/06
MindBio Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13/05
MindBio Therapeutics Scientists Present Landmark Women's Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month	03/05
Mindbio Therapeutics Corp. Announces Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3	02/05
MindBio Therapeutics Announces Landmark Women's Health CNS Drug Trials	01/05
MindBio Therapeutics Corp. Announces the Regulatory Approval of A Series of Clinical Trials in Women's Health Using MB22001	30/04
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry	24/04
MindBio Beginning Landmark Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	20/03
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder	20/03
MindBio Therapeutics Receives Final Approval to Conduct Phase 2B Trial Microdosing Mb22001 in Patients With MDD	04/03
Mindbio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder	04/03
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	27/02
MindBio Therapeutics Corp. Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial	26/02
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial	15/02
MindBio Therapeutics Corp. Completes World First Take Home Phase 2a Microdosing Depression Trial	14/02
MindBio Therapeutics Corp. Announces Completion of Landmark Phase 2A LSD Microdosing Clinical Trial in Distressive Disorder	30/01
MindBio Therapeutics Corp. CEO Provides End of Year Video Update on Phase 2 Clinical Trials	20/12
MindBio Therapeutics Corp. Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer	31/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues MindBio Therapeutics Corp.

Actions

MBIO

CA60256C1086

Autres langues

Filtres